Heart Transplant Market Report Outlook (2022-2033)

Increasing Prevalence of End-Stage Heart Failure

The key regulator fuelling the growth of the Heart Transplant Market is the increasing number of cases of end-stage heart failure worldwide, surpassing 64 million, and expected to increase with the growing geriatric population and cardiovascular conditions. Illnesses such as coronary artery diseases, hypertensive disorders, and viral cardiomyopathy frequently lead to irreversible heart failures, and the sole cure at this stage is a transplant, ensuring a 12-14-year survival rate. Advanced technologies in the form of echocardiographies and/or cardiac MRI are used for prior screening of potential recipients, and awareness programs and registering centers facilitate waiting list management. This leads to increasing demand for organ acquisitions, instrumentation, and immunosuppressives, increasing by 5–10% in developed countries, thus contributing directly to market revenue generation.

Advancements in Organ Preservation and Xenotransplantation

A significant market opportunity is presented by the advancements and innovations that have occurred within organ preservation and the development of xenotransplantation, which would solve the recurrent shortage of available organs and prevent the annual death of over 20% of the waiting list recipients. Machine perfusion technology, such as hypothermic oxygen perfusion, has extended the available time for using the heart from 4–6 hours to 12+ hours by restoring the organ’s energy and protecting the cells from ischemic-reperfusion injury, increasing the number of available organs by 20–30%. Organized, on the other hand, are the use of pig heart organs that have been gene-edited using the CRISPR technique and have shown the ability to survive for up to two months post-human trials, and the potential for an unlimited supply of organs.

The "Heart Transplant Market Size and Forecast (2022 - 2033)" report provides a detailed analysis of the market covering below areas:

• Heart Transplant Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Heart Transplant Market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• Heart Transplant Market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Heart Transplant Market
• Detailed company profiles, including SWOT analysis

The geographical scope of the Heart Transplant Market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America dominates the Heart Transplant Market with the largest revenue share, attributed to advanced transplant networks like UNOS, high procedure volumes, substantial R&D funding, and favorable reimbursement policies.

Asia Pacific is projected as the fastest-growing region, propelled by expanding healthcare access in China and India, rising cardiovascular disease prevalence, government investments in transplant infrastructure, and growing organ donation programs.

• The report includes qualitative and quantitative data in the Heart Transplant Market across type, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the Heart Transplant Market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the Heart Transplant Market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the Heart Transplant Market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 10 cover the Heart Transplant Market segments by type, end user, and geography (including North America, Europe, Asia Pacific, the Middle East and Africa, and South and Central America). They cover the market volume, revenue forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the Heart Transplant Market. Companies have been profiled on the basis of their key facts, business descriptions, products and services, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix, is inclusive of a brief overview of the company, a list of abbreviations, and a disclaimer.

The Heart Transplant Market is evaluated by gathering qualitative and quantitative data post-primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the Heart Transplant Market are:

• In June 2025, CARMAT announced the first implants of its Aeson® artificial heart in a commercial set-up, outside the European Union.
• In March 2025, Boston Scientific Corporation announced to have entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that developed the TIVUS™ Intravascular Ultrasound System. An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation for hypertension.
• In January 2025, SynCardia Systems, LLC (“SynCardia”, or the “Company”) announced that the China National Intellectual Property Administration notified the Company of the administration’s decision to grant SynCardia its first patent covering the Company’s next-generation total artificial heart. This patent describes novel technology aimed at eliminating external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle.